NDAQ:GH - Post Discussion
Post by
whytestocks on Feb 23, 2024 8:00pm
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom
Just In: $GH Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test | BenzingaThursday, Guardant Health Inc (NASDAQ:GH) reported fourth-quarter 2023 sales of $155.1 million, up 22% Y/Y, beating the consensus of...
GH - Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test | Benzinga
Be the first to comment on this post